

PA Criteria	Criteria Details						
<b>Covered Uses (FDA approved indication)</b>	Releuko is a biosimilar to Neupogen. Colony-stimulating factors (CSFs) are hematopoietic growth factors that regulate the growth and differentiation of cells towards the myeloid and erythroid lineages. Myeloid growth factors (MGFs), such as granulocyte colony-stimulating factors (G-CSF), are primarily used to reduce the incidence of febrile neutropenia (FN) in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy.						
<b>Exclusion Criteria</b>	None.						
<b>Required Medical Information</b>	Medical records supporting the request must be provided.						
<b>Age Restriction</b>	None.						
<b>Prescriber Restrictions</b>	None.						
<b>Coverage Duration</b>	One year. Dose will be approved according to the FDA-approved labeling or within accepted standards of medical practice.						
<b>Other Criteria/Information</b>	Refer to the Gold Coast Health Plan Medicare Part B Reference and Summary of Evidence document. <table border="1" data-bbox="496 961 1513 1171"> <thead> <tr> <th>HCPCS</th> <th>Description</th> <th>Billing Units/How Supplied</th> </tr> </thead> <tbody> <tr> <td>Q5125</td> <td>Releuko (filgrastim-ayow)</td> <td><b>Billing unit: 0.1 mg</b>  300 mcg/mL SDV, 480 mcg/1.6 mL SDV, 300 mcg/0.5 mL PFS, and 480 mcg/0.8 mL PFS</td> </tr> </tbody> </table>	HCPCS	Description	Billing Units/How Supplied	Q5125	Releuko (filgrastim-ayow)	<b>Billing unit: 0.1 mg</b>  300 mcg/mL SDV, 480 mcg/1.6 mL SDV, 300 mcg/0.5 mL PFS, and 480 mcg/0.8 mL PFS
HCPCS	Description	Billing Units/How Supplied					
Q5125	Releuko (filgrastim-ayow)	<b>Billing unit: 0.1 mg</b>  300 mcg/mL SDV, 480 mcg/1.6 mL SDV, 300 mcg/0.5 mL PFS, and 480 mcg/0.8 mL PFS					

STATUS	DATE REVISED	REVIEW DATE	APPROVED/REVIEWED BY	EFFECTIVE DATE
Created	3/26/2025	3/26/2025	Dawn Shojai, PharmD, Senior Pharmacy Benefit Consultant (PSG)	N/A
Approved	N/A	5/15/2025	Pharmacy & Therapeutics (P&T) Committee	5/15/2025